In short
Gadoquatrane is an innovative contrast agent being studied for use in magnetic resonance imaging (MRI). This article explores the ongoing clinical trials investigating Gadoquatrane's safety, effectiveness, and potential advantages over existing contrast agents for improving MRI scans of various body regions.
At a glance
- Drug Name
- Gadoquatrane (BAY1747846)
- Type
- Gadolinium-based contrast agent (GBCA)
- Purpose
- Enhance MRI scans for better visualization of lesions and pathologies
- Dosage
- 0.04 mmol Gd/kg body weight (typical study dose)
- Administration
- Single intravenous injection during MRI examination
- Target Areas
- Brain, spinal cord, and other body regions
- Key Advantage
- Potential for lower gadolinium dose compared to current GBCAs
- Study Populations
- Adults and children with suspected pathologies; healthy volunteers
- Main Outcomes
- Image quality, lesion detection, diagnostic confidence, safety profile
- Comparison
- Versus approved macrocyclic GBCAs at 0.1 mmol Gd/kg
What is Gadoquatrane?
Gadoquatrane, also known as BAY1747846, is a new type of contrast agent being developed for use in Magnetic Resonance Imaging (MRI) scans. Contrast agents are substances given to patients before or during an MRI to help create clearer and more detailed images of the inside of the body. This can help doctors better identify and evaluate various health problems.
Gadoquatrane belongs to a class of contrast agents called gadolinium-based contrast agents (GBCAs). These agents contain a rare earth element called gadolinium, which is essential for improving the contrast and signal intensity in MRI scans.
How Does Gadoquatrane Work?
When injected into a patient's vein, Gadoquatrane travels through the bloodstream and into various tissues of the body. The gadolinium in the contrast agent interacts with the magnetic fields used in MRI, causing certain areas of the body to appear brighter or darker on the resulting images. This helps radiologists and doctors see more details and potentially identify abnormalities that might not be visible on a regular, non-contrast MRI.
What Conditions Can Gadoquatrane Help Diagnose?
Gadoquatrane is being studied for use in diagnosing a wide range of conditions, including:
- Brain and spinal cord disorders: Such as tumors, infections, or inflammatory conditions
- Other body regions: Including organs, soft tissues, and blood vessels throughout the body (except the brain and spinal cord)
The enhanced images provided by Gadoquatrane can help doctors detect, locate, and assess the extent of various abnormalities, potentially leading to more accurate diagnoses and better treatment planning.
Advantages of Gadoquatrane
Researchers are developing Gadoquatrane with several potential advantages over existing contrast agents:
- Lower gadolinium dose: Gadoquatrane is designed to use a lower amount of gadolinium (0.04 mmol Gd/kg) compared to standard contrast agents (0.1 mmol Gd/kg). This may help reduce the potential risks associated with gadolinium retention in the body.
- Improved image quality: Despite the lower dose, Gadoquatrane aims to provide similar or better image quality compared to existing contrast agents.
- Potential for wider use: Studies are being conducted to evaluate Gadoquatrane's effectiveness in various body regions, which could make it a versatile option for different types of MRI scans.
Current Clinical Trials
Gadoquatrane is currently undergoing several clinical trials to evaluate its safety, effectiveness, and optimal dosing. These studies include:
- A study in children from birth to under 18 years old to understand how Gadoquatrane moves through the body and assess its safety.
- Trials comparing Gadoquatrane to existing contrast agents for brain and spinal cord imaging.
- Studies evaluating Gadoquatrane for imaging other parts of the body.
- A study in healthy Chinese male participants to assess safety and blood levels of Gadoquatrane at different doses.
Safety and Side Effects
As with any medical intervention, researchers are closely monitoring the safety of Gadoquatrane. The ongoing clinical trials are designed to identify any potential side effects or adverse reactions. Common things that doctors look out for include:
- Injection site reactions
- Allergic reactions
- Changes in vital signs (blood pressure, heart rate, body temperature)
- Any unexpected medical problems that occur after receiving the contrast agent
It's important to note that as a new contrast agent still in development, the full safety profile of Gadoquatrane is not yet established. The current clinical trials aim to gather more information about its safety in different patient populations.
How is Gadoquatrane Administered?
Gadoquatrane is given as an intravenous injection, which means it's injected directly into a vein. This is typically done just before or during the MRI scan. The dose is calculated based on the patient's body weight, with the current studies using a dose of 0.04 mmol Gd/kg body weight.
After receiving Gadoquatrane, patients typically undergo the MRI scan, which can last anywhere from 15 minutes to over an hour, depending on the type of scan and the area being examined.